Long-term continuation of levetiracetam in patients with refractory epilepsy

被引：112

作者：

Krakow, K

Walker, M

Otoul, C

Sander, JWAS

机构：

[1] Univ Frankfurt, Dept Neurol, D-60590 Frankfurt, Germany

[2] UCL, Inst Neurol, Dept Clin Neurol, Epilepsy Res Grp, London, England

[3] Natl Soc Epilepsy, Gerrards Cross, England

[4] UCB Bioprod SA, Braine lAlleud, Belgium

来源：

NEUROLOGY | 2001年 / 56卷 / 12期

关键词：

D O I：

10.1212/WNL.56.12.1772

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The long-term continuation (retention) rate, efficacy, and safety data of the new antiepileptic drug levetiracetam (LEV) was evaluated in all patients with epilepsy exposed to the drug during its developmental program (n = 1,422). The retention rate was estimated to be 60% after 1 year and 32% after 5 years. Thirty-nine percent (512/1,325) of patients had a seizure reduction of greater than or equal to 50%, and 13% (183/1,422) became seizure-free for at least 6 months. LEV seems an effective and well tolerated new antiepileptic drug.

引用

页码：1772 / 1774

页数：3

共 10 条

[1] Levetiracetam for partial seizures - Results of a double-blind, randomized clinical trial [J].

Cereghino, JJ ;

Biton, V ;

Abou-Khalil, B ;

Dreifuss, F ;

Gauer, LJ ;

Leppik, I .

NEUROLOGY, 2000, 55 (02) :236-242

[2] Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic [J].

Kellett, MW ;

Smith, DF ;

Stockton, PA ;

Chadwick, DW .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 66 (06) :759-763

[3] Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy [J].

Klitgaard, H ;

Matagne, A ;

Gobert, J ;

Wülfert, E .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 353 (2-3) :191-206

[4] Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy [J].

Lhatoo, SD ;

Wong, ICK ;

Sander, JWAS .

EPILEPSIA, 2000, 41 (03) :338-341

[5]

Löscher W, 1998, J PHARMACOL EXP THER, V284, P474

[6] The new antiepileptic drugs: A systematic review of their efficacy and tolerability [J].

Marson, AG ;

Kadir, ZA ;

Hutton, JL ;

Chadwick, DW .

EPILEPSIA, 1997, 38 (08) :859-880

[7] Pharmacokinetic profile of levetiracetam: toward ideal characteristics [J].

Patsalos, PN .

PHARMACOLOGY & THERAPEUTICS, 2000, 85 (02) :77-85

[8] The impact of new antiepileptic drugs on the prognosis of epilepsy: Seizure freedom should be the ultimate goal [J].

Walker, MC ;

Sander, JWAS .

NEUROLOGY, 1996, 46 (04) :912-914

[9] Difficulties in extrapolating from clinical trial data to clinical practice: The case of antiepileptic drugs [J].

Walker, MC ;

Sander, JWAS .

NEUROLOGY, 1997, 49 (02) :333-337

[10] The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy [J].

Wong, ICK ;

Chadwick, DW ;

Fenwick, PBC ;

Mawer, GE ;

Sander, JWAS .

EPILEPSIA, 1999, 40 (10) :1439-1445

← 1 →